SEC Form 4 · accession 0001062993-16-012534
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Toby Wegman
Director
Period of report
Nov 29, 2016
Accepted (ET)
Nov 29, 2016 · 5:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.001 par valueF1,F2 | Nov 29, 2016 | S | 10,000 | $48.0832 | D | 949,973 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $48.0832 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $48.00 to $48.2501. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2These shares are held in trust on behalf of the reporting person and Mr. Thomas Wegman. The reporting person is the co-trustee of the trust with Mr. Thomas Wegman. The reporting person disclaims beneficial ownership of the shares held by the trust except to the extent of the reporting person's pecuniary interest therein.